. 2014 Jun;33(6):267–276. doi: 10.5732/cjc.013.10134

Table 3. Summary of clinical studies on targeted agents for treatment of pancreatic cancer.

Authors and reference	Year of publication	Agent	Arm	Phase	No. of patients	Percentage of patients (%)		Response rate (%)	Median overall survival (months)
Authors and reference	Year of publication	Agent	Arm	Phase	No. of patients	Locally advanced pancreatic cancer	Metastatic pancreatic cancer	Response rate (%)	Median overall survival (months)
Small molecule
Moore et al.[65]	2003	MMP inhibitor	BAY 12-9566 vs. GEM	III	138	38^a	62	1	3.7
Moore et al.[65]	2003	MMP inhibitor	BAY 12-9566 vs. GEM	III	139	35^a	65	5	6.6
Van Cutsem et al.[66]	2004	Farnesyltransferase inhibitor	GEM + tipifarnib vs. GEM + placebo	III	341	NA	NA	6	6.2
Van Cutsem et al.[66]	2004	Farnesyltransferase inhibitor	GEM + tipifarnib vs. GEM + placebo	III	347	NA	NA	8	5.9
Senderowicz et al.[67]	2007	EGFR	GEM + erlotinib vs. GEM + placebo	III	261	23	77	8.6	6.5
Senderowicz et al.[67]	2007	EGFR	GEM + erlotinib vs. GEM + placebo	III	260	24	76	7.9	6.0
Moore et al.[34]	2007	EGFR	GEM + erlotinib vs. GEM + placebo	III	285	23.5	76.5	8.6	6.2
Moore et al.[34]	2007	EGFR	GEM + erlotinib vs. GEM + placebo	III	284	25	75	8	5.9
Kindler et al.[39]	2011	VEGFR	GEM + axitinib vs. GEM + placebo	III	314	25^b	72	5	8.5
Kindler et al.[39]	2011	VEGFR	GEM + axitinib vs. GEM + placebo	III	316	23^b	72	2	8.3
Monoclonal antibody
Philip et al.[36]	2010	EGFR	GEM + Cetuximab vs. GEM	III	372	21	79	12	6.3
Philip et al.[36]	2010	EGFR	GEM + Cetuximab vs. GEM	III	371	22	78	14	5.9
Kullmann et al.[37]	2009	EGFR	Cetuximab + GEM/oxaliplatin	II	61	0	100	33	6.9
Kindler et al.[68]	2010	VEGF-A	GEM + bevacizumab vs. GEM + placebo	III	302	16	84	13	5.8
Kindler et al.[68]	2010	VEGF-A	GEM + bevacizumab vs. GEM + placebo	III	300	15	85	10	5.9
Combination of small molecule and monoclonal antibody
Van Cutsem et al.[40]	2009	VEGF-A	GEM + erlotinib + bevacizumab vs. GEM + erlotinib	III	306	0	100	13.5	7.1
Van Cutsem et al.[40]	2009	VEGF-A	GEM + erlotinib + bevacizumab vs. GEM + erlotinib	III	301	0	100	8.6	6.0
Ko et al.[69]	2010	VEGF and EGFR	Bevacizumab + erlotinib	II	36	0	100	2.8	3.4

^aThe given number includes stage III and lower disease. ^bRemaining belongs to stage II. EGFR, epidermal growth factor receptor; GEM, gemcitabine; MMP, matrix metalloproteinase; NA, not available; VEGF(R), vascular endothelial growth factor (receptor).